A New England Journal of Medicine study published yesterday found success in administering dostarlimab, an immunotherapy drug, to a group of 103 cancer patients instead of traditional methods such as chemotherapy, radiation or surgery. All 49 patients of the first cohort, who had rectal cancer, had their cancer disappear and continued treatment with nonoperative management. The second cohort of patients had other cancers, and 35 of 54 in that group had their cancer eradicated. Thirty-three continued with nonoperative treatment. 

Related News Articles

Headline
The House Ways and Means Subcommittee on Health held a hearing Nov. 19 to discuss improvements to care coordination and delivery to prevent and treat chronic…
Headline
Elizabeth Dabrowski, M.D., pediatric endocrinologist at Children’s Wisconsin, and Matthew Edwards, R.D., diabetes care and education specialist at Children’s…
Headline
The American Heart Association released a study Oct. 28 that found disruptions to people’s circadian rhythm can increase their risk of cardiovascular disease…
Headline
A JAMA study published yesterday analyzed the health characteristics of individuals projected to lose Medicaid coverage due to work requirements included in…
Headline
The Department of Health and Human Services announced Sept. 30 that it is doubling its funding for childhood cancer research from $50 million to $100 million…
Headline
The White House Sept. 9 released its “Make Our Children Healthy Again” strategy report, created to address childhood chronic diseases. The report highlights…